Halcion

(Triazolam)

ApprovedSmall molecule

Pfizer

Halcion is one of 36 small molecule programs targeting Sedation. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AgeCompleted

AgePreclinical

Completed

Competition

Competitive Landscape

48 competitors in Age

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Rapamune

PPrism Pharmaceuticals

Halcion

1 4

Venclexta

AbbVie

Phase 1

3 5

Acotiamide

GGetz Pharma

Phase 3

1 6

APG-115

Ascentage Pharma Group Inc.

Phase 2

1 7

APG-2575

Ascentage Pharma Group Inc.

Phase 2

1 8

Funduscein-25

FFalcon

Phase 2

1 9

Imbruvica

PPharmacyclics LLC.

Phase 1

1 10

Opalustre

CCairo University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

MPA

NCT03954483

Clinical

Trials by Indication[1]

Absorption1 trial

Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT01017926

Driving1 trial

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01888497·59 enrolled

Age1 trial

Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

Completed·AAkili Interactive Labs, Inc.·N/A·NCT02822937·18 enrolled

Oral1 trial

A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT01421043·34 enrolled

MPA1 trial

Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal

Recruiting·UUniversity of Manitoba·N/A·NCT03954483·42 enrolled

4 more indications

Treatment1 trial

Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient

Completed·UUniversity of Pittsburgh·N/A·NCT03360123·4 enrolled

Sedation1 trial

Oral Versus Intravenous Sedation for Ocular Procedures

Completed·—·Phase 4·NCT03246724·327 enrolled

Esketamine1 trial

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01780259·58 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 26, 1985

HALCION

NDA NDA017892

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Triazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA017892). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Halcion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Absorption1 trial

Driving1 trial

Age1 trial

Oral1 trial

MPA1 trial

Treatment1 trial

Sedation1 trial

Esketamine1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News